Title:
MODIFIED PROTEIN, DRUG, PROPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE, AND METHOD FOR PRODUCING MODIFIED PROTEIN
Document Type and Number:
WIPO Patent Application WO/2019/177056
Kind Code:
A1
Abstract:
This modified protein is characterized by: comprising a protein multimer having an amino acid sequence in which the α1 domain of HLA-G and the α3 domain of HLA-G are linked; and at least one amino acid residue in the amino acid sequence constituting the protein being PEGylated by polyethylene glycol (PEG).
Inventors:
MAENAKA KATSUMI (JP)
KUROKI KIMIKO (JP)
MAEDA NAOYOSHI (JP)
YAMADA CHISATO (JP)
TAKAHASHI AMI (JP)
KUROKI KIMIKO (JP)
MAEDA NAOYOSHI (JP)
YAMADA CHISATO (JP)
TAKAHASHI AMI (JP)
Application Number:
PCT/JP2019/010366
Publication Date:
September 19, 2019
Filing Date:
March 13, 2019
Export Citation:
Assignee:
UNIV HOKKAIDO NAT UNIV CORP (JP)
International Classes:
C07K14/74; A61K38/17; A61K47/60; A61P29/00; C07K17/00; C12P21/02; C12N15/12
Domestic Patent References:
| WO2010052228A1 | 2010-05-14 |
Foreign References:
| JP2015140322A | 2015-08-03 |
Other References:
NEDO ACHIEVEMENT REPORT, 17 May 2011 (2011-05-17), pages 1 - 25, Retrieved from the Internet [retrieved on 20190509]
STROHL, W. R.: "Fusion Proteins for Half-Life Extension of biologics as a Strategy to Make Biobetters", BIODRUGS, vol. 29, no. 4, August 2015 (2015-08-01), pages 215 - 239, XP055564076, doi:10.1007/s40259-015-0133-6
STROHL, W. R.: "Fusion Proteins for Half-Life Extension of biologics as a Strategy to Make Biobetters", BIODRUGS, vol. 29, no. 4, August 2015 (2015-08-01), pages 215 - 239, XP055564076, doi:10.1007/s40259-015-0133-6
Attorney, Agent or Firm:
KIMURA Mitsuru (JP)
Download PDF:
Previous Patent: LITHIUM ION SECONDARY BATTERY
Next Patent: SUBSTRATE FOR RELEASE SHEETS, AND RELEASE SHEET
Next Patent: SUBSTRATE FOR RELEASE SHEETS, AND RELEASE SHEET